Core Insights - Zoetis Inc. (NYSE:ZTS) has been recognized as one of the 14 Best Pharma Dividend Stocks to Buy in 2026 [1] - BofA downgraded Zoetis from Buy to Neutral and reduced its price target from $165 to $135 [2] - Health Canada approved Portela™ (relfovetmab injection) for osteoarthritis pain relief in cats, which is expected to be commercially available in Canada and the EU by 2026 [3][4] Product Development - Portela is designed to provide up to three months of pain relief from osteoarthritis with a single injection, targeting anti-nerve growth factor (NGF) [3] - A nine-month field trial in Europe demonstrated Portela's effectiveness in reducing OA pain and its tolerability in cats, including those with kidney disease [4] - The approval of Portela signifies Zoetis's commitment to developing innovative therapies for companion animals, adding to its existing OA pain treatment portfolio [5] Company Positioning - Zoetis is the largest global animal health company, focusing on advancing animal care worldwide [6] - Despite the potential of Zoetis as an investment, some analysts suggest that certain AI stocks may offer greater upside potential with less downside risk [6]

Group 1 - Zoetis Inc. is recognized as one of the 15 Dividend Stocks with low payout ratios and strong upside potential [1] - Morgan Stanley has lowered its price target for Zoetis to $160 from $175 while maintaining an Overweight rating, highlighting the attractive opportunities in healthcare technology and providers for 2026 [2] - Zoetis received regulatory approval from Health Canada for Portela™ (relfovetmab injection), a treatment for osteoarthritis pain in cats, which provides three months of pain relief with a single injection [3][4] Group 2 - Clinical studies demonstrated that Portela effectively reduced osteoarthritis pain in cats and was well tolerated, including in those with early-stage kidney disease [4] - Zoetis operates as the world's largest animal health company, focusing on advancing care for animals and supporting animal well-being across both companion and livestock markets [5]